Latest Iovance Biotherapeutics News & Updates

See the latest news and media coverage for Iovance. We track all announcements, press releases, and industry mentions in real time, all in one place.

Iovance Biotherapeutics (Iovance)

Biopharmaceutical company developing and commercializing personalized cancer immunotherapies

iovance.com

Headquarters: Philadelphia, United States
Founded year: 2007
Company type: Public company
Number of employees: 1,000–5,000
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Iovance Biotherapeutics (Iovance)

In short: Iovance reported record third-quarter revenue and positive lifileucel data across sarcoma, lung cancer and melanoma.

Company announcements

Yesterday Iovance

Iovance reports record third quarter 2026 revenue of ~$122M

Total revenue rose ~80% year-over-year, U.S. Amtagvi revenue grew ~77%, and gross margin reached ~60%.

September 29 Iovance

Iovance raises full year 2026 revenue guidance

Revenue outlook increases to $410-$420 million due to strong demand for Amtagvi and Proleukin and expanding treatment centers.

August 6 Iovance

Iovance reports record second quarter 2026 revenue of ~$99M

Total revenue increased 66% year-over-year, gross margin reached 56%, and FDA granted Fast Track for lifileucel in soft tissue sarcomas.

July 30 Iovance

Iovance reports Q2 2026 financial results and corporate updates

The company announced strong business momentum and will host a live audio webcast at 8:30 a.m. ET with a replay available.

Media coverage

Yesterday MarketScreener

Iovance Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Iovance Biotherapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported revenue...

October 29 MSN

Iovance Biotherapeutics, Inc. reports 24.6% ORR in phase 2 IOV-LUN-202 trial and plans sBLA in 2027

Iovance Biotherapeutics, Inc. announced updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial evaluating lifileucel in previously treated non-squamous metastatic non-small-cell...

October 27 RTTNews

Iovance Biotherapeutics Stock Plunges 36% After Updated Lung Cancer Trial Data

Iovance Biotherapeutics, Inc. ( IOVA) is down 35.76 percent, losing $5.30 to $9.52 on the Thursday. The decline follows updated results from Cohorts 1 and...

October 23 Seeking Alpha

Iovance sees long-term response for Amtagvi in first-line melanoma (IOVA:NASDAQ)

Phase 2 data show Amtagvi plus Keytruda delivered strong frontline advanced melanoma responses. Read...

Never miss news about Iovance

Track Iovance and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Iovance competitors & trending companies

Browse news for competitors to Iovance and other trending companies.